KRAS and colorectal carcinoma: Once combined KRAS with m3, the AUC values elevated from 0.824 to 0.866 in all patients, which was 0.878 in patients with early CRC and 0.825 in patients with advanced CRC (Figures 3G–I), indicating that the combination of m3 and KRAS were more suitable for patients with early CRC.